The way Forward
Executive Summary
Q2: For people with dementia, does memantine, when compared to placebo/comparator, produce benefits/harm in the specified outcomes in non-specialist health settings?
INT J TUBERC LUNG DIS 22(2):197–205 http://dx.doi.org/10.5588/ijtld.17.0245
HIV/AIDS - Research and Palliative Care 2016:8 183–193
Health Policy Plan (2017) 32 (5): 603-612; 10 pp. 318 kB
A Cost-Efficiency Analysis for the Kyrgyz Republi
Reporting period January 2015 – December 2015
Bucharest, April 2016
Vaccination programmes against COVID-19 and seasonal influenza are currently being implemented in parallel in many countries. Administration of both vaccines during the same visit has potential advantages. This document presents the evidence related to coadministration of Covid-19 and influenza vacc...ines and the interim guidance.
more
Clinical Infectious Diseases
1586 - 1594 • CID 2016:62 (15 June) • HIV/AIDS
HIV-related advocacy evaluation training for civil society organisations
Overcoming barriers in low- and middle-income countries
For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the various dimensions of access to HCV diagnostics and pha...rmaceutical products, including product pricing, the regulatory environment and patent status, which together shape the national hepatitis response in different settings. It highlights key areas for action by ministries of health and other government decision-makers, pharmaceutical manufacturers and technical partners.
more
3ie Impact Evaluation Report 39
The Lay Counselor Cadre in Botswana
Annex 1: Measuring progress towards targets
Annex 2: Modelling the impact of the 90-(90)-90 strategy
Annex 3: Investment packages by country setting
Annex 4: Country strategies
Annex 5: Strategic frameworks for research and development for new tools
Annex 6 : Estimating the cost of the 90-(90)-...90 strategy
Accessed November 2017
more